Combination products
OwnerBaltazar Gomez-Mancilla, Fabrizio Gaspariniinventors
Life of this patent
Estimating the term…
Abstract
The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor.
Claims28
The use of an mGluR modulator in combination with at least one of
- i) L-dopa, or
- ii) a dopa decarboxylase inhibitor, or
- iii) a catechol-O-methyl transferase inhibitor
- iv) a dopamine agonist
- or in any case a pharmaceutically acceptable salt thereof;
- for the treatment, prevention or delay of progression of Parkinson's Disease and/or a disorder associated with Parkinson's Disease.
Use according to any preceding claim, wherein the modulator is a compound of the formula (I)
- wherein
- R1 represents optionally substituted alkyl or optionally substituted benzyl;
- and
- R2 represents hydrogen (H), optionally substituted alkyl or optionally substituted benzyl;
- or
- R1 and R2 form together with the nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
- R3 represents halogen, alkyl, alkoxy, alkylamino or dialkylamino;
- R4 represents hydroxy (OH), halogen, alkyl or alkoxy;
- Q represents CH, CR4 or N;
- V represents CH, CR4 or N;
- W represents CH, CR4 or N;
- X represents CH or N;
- Y represents CH, CR3 or N;
- Z represents CH2, NH or O;
- and
- provided that Q, V and W are not N at the same time;
- in free base or acid addition salt form.
Use according to any preceding claim, wherein the disorder is Parkinson's associated levodopa (L-dopa) induced dyskinesia.
Use according to any preceding claim, wherein the disorder is Parkinson's Disease non-L-dopa induced dyskinesia.
Use according to any preceding claim, wherein the Dopa decarboxylase inhibitors are, carbidopa or benserazide.
Use according to any preceding claim, wherein the Catechol-O-methyl transferase inhibitors are tolcapone or entacapone.
Use according to any preceding claim, wherein the Dopamine agonists are bromocriptine, pergolide, pramipexole, ropinirole, cabergoline, apomorphine or lisuride.
A method for the treatment, prevention or delay of progression of Parkinson's Disease and/or a disorder associated with Parkinson's Disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of an mGluR modulator.
A combination comprising an mGluR modulator or a pharmaceutically acceptable salt thereof, and at least one of
- v) L-dopa, or
- vi) a dopa decarboxylase inhibitor, or
- vii) a catechol-O-methyl transferase inhibitor
- viii) a dopamine agonist
- or in any case a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising an mGluR modulator and at least one of
- ix) L-dopa, or
- x) a dopa decarboxylase inhibitor, or
- xi) a catechol-O-methyl transferase inhibitor
- xii) a dopamine agonist
- for the treatment, prevention or delay of progression of Parkinson's Disease and/or a disorder associated with Parkinson's Disease.
A kit comprising
- (a) an amount of an mGluR modulator or a pharmaceutically acceptable salt thereof in a first unit dosage form;
- (b) an amount of at least one active ingredient selected from L-dopa, or a dopa decarboxylase inhibitor, or a catechol-O-methyl transferase inhibitor, or a dopamine agonist or, in each case, where appropriate, a pharmaceutically acceptable salt thereof;
- and
- (c) a container for containing said first, second etc. unit forms;
- and
- (d) instructions for using the modulator in the treatment, prevention or delay of progression of Parkinson's Disease and/or a disorder associated with Parkinson's Disease.
Dependencies are inferred from the claim text.